BRCA2 and ovarian neoplasm: In order to determine if this is indeed the case, we searched the AACR Project GENIE database (aacr.org) and found that a significant proportion of ovarian tumors with a BRCA1 and/or a BRCA2 mutation also had a TP53 mutant compared with tumors that were BRCA1 and BRCA2 wild-type (85.9% versus 69.1% respectively, p<0.001).